Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Questcor evaluates Acthar as potential new treatment for nephrotic syndrome

Oct. 29, 2008

Flupirtine mechanism of action may be useful in treating overactive bladder

Oct. 29, 2008

Recent Takeda patent reports new 5-HT2C receptor agonists for urinary incontinence

Oct. 15, 2008

Protox presents positive 12-month data from BPH study

Oct. 10, 2008

Watson receives FDA approval for Rapaflo for benign prostatic hyperplasia

Oct. 9, 2008

AEterna completes enrollment in phase III study of LHRH antagonist cetrorelix in BPH

Oct. 7, 2008

Kringle files IND with FDA for phase I clinical trial of recombinant human HGF in renal disease

Oct. 6, 2008

Ranbaxy patents novel muscarinic receptor antagonists

Sep. 29, 2008

EMEA expands orphan medicinal product status for Neo-Bladder Augment

Sep. 25, 2008

Recent efficacy and safety results presented from a phase II NX-1207 study in LUTS-BPH

Sep. 19, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...